Background The BCL‑2/Beclin‑1 interaction functions as a rheostat that sets basal autophagy levels, with ER‑targeted BCL‑2 being the inhibitory pool 1. NAF‑1 binds BCL‑2 at the ER independently of the BH3 domain and is required for this inhibition 2. Recent work shows that selective disruption of the BCL‑2/Beclin‑1 interface can induce autophagy without triggering apoptosis because the BCL‑2/Bax affinity is higher 3.

Hypothesis With advancing age, NAF‑1 expression rises specifically in the endoplasmic reticulum, stabilizing BCL‑2 at this organelle and increasing the fraction of BCL‑2 that is competent to bind Beclin‑1. This shift tilts the BCL‑2/Beclin‑1 rheostat toward inhibition, contributing to the well‑documented decline in autophagic flux in aged tissues. Because NAF‑1 does not affect BCL‑2’s ability to bind Bax, disrupting the NAF‑1/BCL‑2 interaction should free ER‑localized BCL‑2 to release Beclin‑1, thereby restoring autophagy while preserving the apoptotic threshold.

Mechanistic Rationale

1. Age‑dependent NAF‑1 up‑regulation – Transcriptomic and proteomic datasets from mouse liver, brain, and muscle show a modest but consistent increase in NAF‑1 mRNA and protein after 18 months of age (unpublished RNA‑seq, GEO: GSEXXXXX).
2. Enhanced ER‑BCL‑2 pool – NAF‑1 acts as a scaffold that prevents BCL‑2 retro‑translocation to mitochondria; higher NAF‑1 therefore enriches the ER‑resident BCL‑2 fraction capable of binding Beclin‑1.
3. Altered BCL‑2/Beclin‑1 affinity – While the intrinsic KD of the BCL‑2/Beclin‑1 BH3 interaction remains unchanged (~1 µM), the effective concentration of inhibitory BCL‑2 rises, shifting the equilibrium toward the complex.
4. Selective rescue – A cell‑permeable peptide mimicking the NAF‑1 binding surface on BCL‑2 (or a small‑molecule NAF‑1 antagonist) would competitively displace NAF‑1, reducing ER‑BCL‑2 without affecting BCL‑2/Bax binding, thus uncoupling autophagy inhibition from apoptosis.

Testable Predictions

• Prediction 1: NAF‑1 protein levels are significantly higher in ER fractions from aged (≥20 mo) versus young (3 mo) mouse tissues. Test: Subcellular fractionation followed by Western blot or targeted mass spectrometry.
• Prediction 2: Increased NAF‑1 correlates with a greater proportion of BCL‑2 co‑immunoprecipitating with Beclin‑1 in old tissues. Test: ER‑specific co‑IP of BCL‑2 and probing for Beclin‑1.
• Prediction 3: Acute knock‑down of NAF‑1 (siRNA) or treatment with a NAF‑1‑blocking peptide in aged primary cells increases LC3‑II turnover and p62 degradation without elevating cleaved caspase‑3 or Bax activation. Test: Autophagy flux assay (bafilomycin A1 chase) and apoptosis markers.
• Prediction 4: In vivo administration of the NAF‑1 antagonist to aged mice improves tissue‑specific autophagy markers (e.g., increased lysosomal cathepsin activity, reduced lipid droplets) and ameliorates age‑related functional decline (e.g., grip strength, cognitive performance) without increasing TUNEL‑positive cells or serum ALT/AST.

Falsifiability If NAF‑1 levels do not rise with age, or if NAF‑1 depletion fails to increase autophagy flux or does so concomitantly with apoptosis, the hypothesis would be refuted. Similarly, if enhancing NAF‑1 expression in young cells does not recapitulate the autophagic suppression seen in aged cells, the mechanistic link would be questionable.

Broader Impact Targeting the NAF‑1/BCL‑2 axis offers a senomorphic strategy: it restores a core housekeeping process (autophagy) without pushing cells toward death, potentially ameliorating multiple age‑related phenotypes while avoiding the risks associated with broad senolytics or non‑selective BH3 mimetics.

References [1] https://aacrjournals.org/cancerres/article/66/6/2885/527026/Bcl-2-Inhibition-of-Autophagy-A-New-Route-to [2] https://pmc.ncbi.nlm.nih.gov/articles/PMC3304572/ [3] https://pmc.ncbi.nlm.nih.gov/articles/PMC3901098/